Financial Performance - Adjusted net profit for 2024 increased by 139% compared to 2023, benefiting from enhanced technology and improved operational efficiency [4]. - Total revenue for the year reached RMB 2.707 billion, reflecting an 11.2% increase compared to RMB 2.434 billion in 2023 [6][11]. - The company achieved a pre-tax loss of RMB 854.853 million for the year, compared to a loss of RMB 196.711 million in 2023 [6]. - Total comprehensive loss increased from RMB 1,968 million for the year ending December 31, 2023, to RMB 8,549 million for the year ending December 31, 2024 [45]. - Adjusted net profit for the year ending December 31, 2024, was RMB 17.1 million, compared to RMB 7.2 million for the year ending December 31, 2023 [50]. - Operating loss for the year was RMB 777,693,000, significantly higher than the operating loss of RMB 51,895,000 in the previous year [94]. - The company reported a net loss of RMB 854,885,000 attributable to ordinary equity shareholders in 2024, compared to a loss of RMB 196,788,000 in 2023 [124]. User Engagement and Growth - As of December 31, 2024, the platform registered users grew to 49.2 million, with an average monthly active user count of 10.1 million, representing a 20% year-over-year increase [4][11]. - The repeat purchase rate for paying users remained strong at 84.7% for the year ended December 31, 2024 [11]. - The company plans to expand its market presence and enhance its product offerings through ongoing research and development initiatives [144]. - The company plans to strengthen its online chronic disease management market leadership by balancing immediate tactical improvements with long-term strategic planning [22]. Revenue Streams - Online retail pharmacy service revenue increased by 8.3% from RMB 1,297.1 million for the year ended December 31, 2023, to RMB 1,404.8 million for the year ended December 31, 2024 [16]. - Revenue from integrated medical services decreased by 34.3% from RMB 983.7 million for the year ended December 31, 2023, to RMB 646.5 million for the year ended December 31, 2024, with a focus on enhancing profitability and sustainable development [30]. - Wholesale revenue surged by 728.5% from RMB 66.5 million for the year ended December 31, 2023, to RMB 550.9 million for the year ended December 31, 2024, leveraging long-term supply chain relationships [31]. - Revenue from customized content and marketing solutions rose by 20.7% from RMB 87.0 million for the year ended December 31, 2023, to RMB 105.1 million for the year ended December 31, 2024, due to improved recognition and outreach efforts [32]. Operational Efficiency - The company focused on developing and integrating emerging technologies, including AI, big data, and cloud computing, to improve platform functionality and user experience [14]. - Inventory turnover days improved from 24.6 days for the year ended December 31, 2023, to 23.1 days for the year ended December 31, 2024 [19]. - Total sales costs increased by 12.6% to RMB 2,191.4 million for the year ended December 31, 2024, from RMB 1,946.9 million for the year ended December 31, 2023, aligning with revenue growth [34]. - Gross profit increased by 5.9% from RMB 487.4 million for the year ended December 31, 2023, to RMB 515.9 million for the year ended December 31, 2024, while overall gross margin decreased to 19.1% [35]. Assets and Liabilities - Non-current assets as of December 31, 2024, amounted to RMB 55.769 million, while current assets totaled RMB 608.325 million [7]. - Trade receivables rose from RMB 241 million as of December 31, 2023, to RMB 363 million as of December 31, 2024 [54]. - Cash and cash equivalents increased from RMB 146.3 million as of December 31, 2023, to RMB 174.6 million as of December 31, 2024, indicating improved cash flow from operating activities [58]. - Total trade and other payables increased to RMB 457,497 thousand in 2024 from RMB 440,451 thousand in 2023, with trade payables rising to RMB 348,627 thousand from RMB 292,944 thousand [134]. Strategic Initiatives - The company plans to allocate RMB 10.73 million (16.0%) of its funds for research and development activities by December 2028 [84]. - A team of approximately 40 software engineers will be hired, with 70% being senior engineers, to enhance AI and big data capabilities in chronic disease management by December 2028 [84]. - The company aims to optimize its infrastructure across various technology domains, including computer vision and natural language processing, to improve user experience and system stability by December 2028 [84]. - The company plans to expand its product range and improve supply chain capabilities with 5.5% of the net proceeds, which is HKD 3.69 million [82]. Governance and Compliance - The board of directors consists of an executive chairman, two executive directors, and several independent non-executive directors, ensuring a diverse governance structure [155]. - The audit committee has reviewed the financial statements and confirmed compliance with applicable accounting standards and regulations [87]. - The company has no significant litigation or arbitration cases as of December 31, 2024 [90]. Capital and Funding - The net proceeds from the global offering amount to approximately HKD 67.09 million, which will be allocated according to the disclosed purposes in the prospectus [80]. - 67.4% of the net proceeds will be used for business expansion, with HKD 45.22 million allocated for this purpose [82]. - The expected timeline for utilizing the net proceeds is by December 2028 [82].
方舟健客(06086) - 2024 - 年度业绩